Dyadic Logo Current.jpg
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
March 15, 2023 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Logo Current.jpg
Dyadic to Participate in Two Upcoming Investor Conferences
February 02, 2023 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Logo Current.jpg
Dyadic Announces Sale of Equity Interest in Alphazyme
January 19, 2023 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
YMAB Investor Alert:
YMAB Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Y-mAbs Therapeutics, Inc.
November 11, 2022 20:00 ET | Kaplan Fox & Kilsheimer LLP
NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the...
Dyadic Logo Current.jpg
Dyadic to Present at Upcoming Industry and Investor Events in September
September 08, 2022 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
qsam.png
QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam®
July 13, 2022 13:32 ET | QSAM Biosciences, Inc.
AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- via Investorwire -- QSAM Biosciences Inc. (OTCQB: QSAM) (the “Company”), a company developing next-generation targeted therapeutic...
Dyadic Logo Current.jpg
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting
July 05, 2022 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Genprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer Treatment
September 26, 2019 08:30 ET | Genprex Inc Registered Shs
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – GNPX)">Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Gene Therapies with...
PRPO logo.png
Makati Medical Center in the Philippines Adopts Precipio’s ICE COLD-PCR Mutation Enrichment Technology for Liquid Biopsies
January 15, 2019 07:47 ET | Precipio, Inc.
NEW HAVEN, Conn., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that Makati Medical Center (MakatiMed) in Manila, the Philippines,...
PRPO logo.png
Precipio Announces Third Quarter 2018 Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues
October 16, 2018 07:47 ET | Precipio, Inc.
Fourth consecutive Quarter of Triple-Digit Year-over-Year Quarterly Revenue Growth; Year-to-Date Revenues Increased 163% over First Three Quarters of 2017 NEW HAVEN, Conn., Oct. 16, 2018 (GLOBE...